ACSD Granted Significant Telemedicine Patent

IRVINE, Calif., June 5, 2024 /PRNewswire/ — ACS Diagnostics, Inc. of Irvine CA, with executive offices in Chattanooga TN, has been granted U.S Patent No. 11,980,452. The patent relates to ACSD’s Cardiac Monitoring CORE technology, specifically ambulatory ECG. The patented CORE device provides for multiple telemedicine related tests , including ECG/EKG, Holter, Event, and Mobile Cardiac Telemetry. The Core monitor integrates a cell phone module to alleviate the necessity for a companion phone for patient transmissions.

This is the fifth CORE technology patent, and relates to a single cardiac monitoring device offering to perform more than one of the above mentioned test modalities. The Core monitor is the only telemedicine device that is patented to offer the worldwide cardiology community all these tests within a one device. With this patent, the days of a provider needing to purchase a different monitor for each test are over.

This technology, and all related test modalities, are being successfully used by thousands of US customers, transmitting ECG patient data 24/7 to our California based IDTF laboratory. The ACSD IDTF laboratory is completely staffed with cardiac technicians to monitor patients and alert physicians to significant cardiac events.

A number of companies provide products for this market, including GE Healthcare, Medtronic, BioTelemetry / Philips, Boston Scientific, Samsung, Hill-Rom, IRhythm Technologies, Johnson & Johnson, OSI/Spacelabs, and a host of smaller players.

ACSD respects intellectual property rights and has a growing portfolio of patents, which are listed at www.ACSD4u.com/patents. ACSD firmly believes in innovation through research and development, and it will vigorously enforce its intellectual property rights.

View original content:https://www.prnewswire.com/news-releases/acsd–granted-significant-telemedicine-patent-302165305.html

SOURCE ACS Diagnsotics

Staff

Recent Posts

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

1 hour ago

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

1 hour ago

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

4 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

4 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

4 hours ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

4 hours ago